Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biofermin R
- Development stage
- Unknown
- Lead developer
- Biofermin Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Biofermin R** is a Japanese prescription intestinal-regulating probiotic preparation developed and manufactured by Biofermin Seiyaku. Its active constituent is the multi-antibiotic-resistant lactic acid bacterial strain *Enterococcus faecium* 129 BIO 3B-R. The live organism can proliferate during treatment with susceptible antibacterial agents, producing lactic acid and helping restore antibiotic-disrupted intestinal microbiota while suppressing overgrowth of potentially harmful organisms. It is marketed in oral powder and tablet formulations for improvement of gastrointestinal symptoms resulting from intestinal-flora abnormalities during administration of specified antibacterial or chemotherapeutic agents. It has also been studied as adjunctive treatment during *Helicobacter pylori* eradication therapy to reduce antibiotic-associated gastrointestinal adverse events.
- Brand names
- Biofermin R
- Other names
- antibiotic-resistant lactic acid bacteriaBiofermin-REnterococcus faecium 129 BIO 3B-Rresistant lactic acid bacteria
Beyond the preview
Go deeper on Biofermin R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biofermin R.